TY - JOUR
T1 - Subcellular preconditioning of stem cells
T2 - Mito-Cx43 gene targeting is cytoprotective via shift of mitochondrial Bak and Bcl-xL balance
AU - Lu, Gang
AU - Jiang, Shujia
AU - Ashraf, Muhammad
AU - Haider, Khawaja Husnain
PY - 2012/5
Y1 - 2012/5
N2 - Aim: To achieve mitochondria-specific expression of connexin-43 (Cx43) transgene for mitochondrial preconditioning in stem cells to improve their survival post-transplantation during heart cell therapy. Methods & results: Cx43- or GFP-encoding adenoviral vectors with a mitochondrial targeting sequence were constructed for transduction of bone marrow Sca-1 + cells (>90% transduction efficiency). Double-fluorescence immunostaining for cytochrome-c and Cx43 supported by western blotting confirmed mitochondria-specific Cx43 expression in adenoviral-mito-Cx43-transduced cells ( Cx43Sca-1 +). Cx43Sca-1 + showed improved survival under lethal oxygen-glucose deprivation culture conditions. Cx43Sca-1 + showed an increased mitochondrial Bcl-xL:Bak ratio and reduced cytochrome-c release into cytosol with concomitantly abolished caspase-3 activity. An in vivo study was performed such that 2 × 10 6 male Cx43Sca-1 + or GFPSca-1 + cells were injected into a female rat model of acute myocardial infarction. DMEM-injected rats served as controls. On day 7 post- transplantation, 4.3-fold higher survival of Cx43Sca-1 + cells (p < 0.05 vs control) and reduced terminal deoxynucleotidyl transferase dUTP nick end labeling positivity in the left ventricle (LV) were observed. In comparison, LV ejection fraction (40.2 ± 0.9%), LV fractional shortening (20.0 ± 1.6%) and LV end diastolic dimension (6.5 ± 0.3 mm) were observed in GFPSca-1 +, and treatment with Cx43Sca-1 + cells improved these parameters (47.6 ± 2.5%, p < 0.05; 27.7 ± 1.2%, p < 0.05; and 5.6 ± 0.1 mm, p < 0.05, respectively), along with concomitant reductions in infarction size (33.7 ± 2.9% vs 39.8 ± 1.4%; p < 0.05). Conclusion: Mitochondria-targeted Cx43 expression is a novel approach to improve stem cell survival in the infarcted heart.
AB - Aim: To achieve mitochondria-specific expression of connexin-43 (Cx43) transgene for mitochondrial preconditioning in stem cells to improve their survival post-transplantation during heart cell therapy. Methods & results: Cx43- or GFP-encoding adenoviral vectors with a mitochondrial targeting sequence were constructed for transduction of bone marrow Sca-1 + cells (>90% transduction efficiency). Double-fluorescence immunostaining for cytochrome-c and Cx43 supported by western blotting confirmed mitochondria-specific Cx43 expression in adenoviral-mito-Cx43-transduced cells ( Cx43Sca-1 +). Cx43Sca-1 + showed improved survival under lethal oxygen-glucose deprivation culture conditions. Cx43Sca-1 + showed an increased mitochondrial Bcl-xL:Bak ratio and reduced cytochrome-c release into cytosol with concomitantly abolished caspase-3 activity. An in vivo study was performed such that 2 × 10 6 male Cx43Sca-1 + or GFPSca-1 + cells were injected into a female rat model of acute myocardial infarction. DMEM-injected rats served as controls. On day 7 post- transplantation, 4.3-fold higher survival of Cx43Sca-1 + cells (p < 0.05 vs control) and reduced terminal deoxynucleotidyl transferase dUTP nick end labeling positivity in the left ventricle (LV) were observed. In comparison, LV ejection fraction (40.2 ± 0.9%), LV fractional shortening (20.0 ± 1.6%) and LV end diastolic dimension (6.5 ± 0.3 mm) were observed in GFPSca-1 +, and treatment with Cx43Sca-1 + cells improved these parameters (47.6 ± 2.5%, p < 0.05; 27.7 ± 1.2%, p < 0.05; and 5.6 ± 0.1 mm, p < 0.05, respectively), along with concomitant reductions in infarction size (33.7 ± 2.9% vs 39.8 ± 1.4%; p < 0.05). Conclusion: Mitochondria-targeted Cx43 expression is a novel approach to improve stem cell survival in the infarcted heart.
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=84861308228&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861308228&partnerID=8YFLogxK
U2 - 10.2217/rme.12.13
DO - 10.2217/rme.12.13
M3 - Article
C2 - 22594326
AN - SCOPUS:84861308228
SN - 1746-0751
VL - 7
SP - 323
EP - 334
JO - Regenerative Medicine
JF - Regenerative Medicine
IS - 3
ER -